Mammotome in the news

New guidelines from Korean medical societies advise selective application of Vacuum-Assisted Excision (VAE) for breast lesions, prioritizing accurate diagnosis over automatic removal.

Mammotome secured a CE mark for its HydroMARK™ Plus Breast Biopsy Site Marker, enabling its distribution across Europe for breast cancer diagnosis and treatment.

Mammotome obtained European regulatory approval for its HydroMARK Plus breast biopsy marker to improve visibility and stability during cancer diagnostics.

Mammotome is expanding its European presence by launching the HydroMARK Plus breast biopsy marker featuring anti-displacement technology and long-term ultrasound visibility.

The FDA cleared Mammotome's new MR-guided biopsy system and site marker designed to streamline tissue sampling within MRI suites.

Mammotome has secured FDA clearance for a new in-room MR breast biopsy system and specialized site markers designed to improve procedural efficiency and biopsy accuracy.

Mammotome has launched a new MRI-guided breast biopsy system that operates directly inside the scanner room to improve clinical efficiency and patient care.

Mammotome is launching the Prima MR, an in-room vacuum-assisted breast biopsy system that uses less tubing and larger needles to improve biopsy efficiency and tissue sample size.

Mammotome launched the Prima MR Dual, an in-room MRI platform for vacuum-assisted breast biopsies designed to improve tissue sampling and workflow efficiency.

Mammotome has launched the first in-room MRI vacuum-assisted breast biopsy system to improve clinician workflow and tissue sample quality.

The breast biopsy devices market is projected to grow significantly due to increased breast cancer prevalence and advancements in diagnostic technology, with key players like Mammotome innovating new systems.

Mammotome and Sirius Medical have signed an exclusive deal to distribute advanced surgical navigation technology for breast cancer treatment in the U.S. and Germany.

Developing breakthrough breast care technologies and diagnostic tools while fostering an inclusive, innovation-focused hybrid workplace.

Mammotome released HydroMARK™ Plus, a new breast biopsy marker designed for enhanced visibility and stability during breast cancer diagnostics and surgery.

Mammotome has introduced the HydroMARK Plus, a dragonfly-shaped breast biopsy marker designed to prevent displacement and enhance long-term ultrasound visibility.

Mammotome has launched the HydroMARK Plus, a new breast biopsy site marker designed to improve ultrasound visibility and prevent movement during surgery.

Mammotome is launching the HydroMark Plus site marker to improve ultrasound visibility and reduce marker movement during breast biopsy surgeries.

Danaher's Leica Biosystems division acquired Devicor Medical Products, including its Mammotome breast-care business, to enhance cancer diagnostics.

Danaher's Leica Biosystems division is acquiring Devicor Medical Products, including the Mammotome breast-care business, to enhance its cancer diagnostics offerings.

The FDA approved the Mammotome revolve biopsy system, which uses dual vacuum technology to collect larger tissue samples more efficiently.